Dysregulation of the Signal Transducer and Activator of transcription (STAT) pathway is implicated in various diseases, particularly cancers and autoimmune disorders, making it a high-priority target in therapeutic antibody and protein development. At Creative Biolabs, we are committed to offering a robust solution for researchers aiming to explore JAK/STAT pathway. Our JAK/STAT selectivity panel is designed to facilitate the evaluation of therapeutic candidates that modulate JAK/STAT signaling, providing insights into their efficacy and potential clinical applications.

Fig.1 Cytokines-JAK/STAT pathway.¹

JAK/STAT Cell-based Reporter Assay

Our JAK/STAT selectivity panel utilizes advanced cell-based reporter assays to measure JAK/STAT signaling activity. The core of this service involves transfecting target cells with reporter constructs that encode a Reporter protein under the control of STAT-responsive elements. When STAT proteins are activated by specific ligands or cytokines, they translocate to the nucleus and bind to these elements, resulting in a measurable increase in reporter gene expression. This technology offers a dynamic and physiologically relevant approach to evaluating the effectiveness of potential therapeutics, as it measures the real-time response of transcriptional activity modulated by STAT proteins.

Advantages

• Comprehensive STAT Coverage
  Our JAK/STAT panel includes assays for STAT1, STAT3, STAT4, STAT5, and STAT6, allowing targeted analysis of individual or multiple STAT pathways. This flexibility enables detailed evaluation of how therapeutic candidates modulate specific JAK/STAT signaling components involved in various disease mechanisms.
• High-Sensitivity Reporter Assays
  We utilize advanced reporter constructs driven by STAT-responsive elements, offering real-time, quantitative analysis of pathway activation or inhibition. This ensures accurate detection of even subtle changes in transcriptional activity, supporting precise dose-response evaluation during early-stage development.
• High-Throughput Screening Platform
  Our service is optimized for high-throughput operation, significantly reducing screening time while maintaining data quality. This efficiency accelerates the selection of lead candidates and shortens the therapeutic development timeline, which is essential for time-sensitive research projects.
• Integrated Data Interpretation
  We provide comprehensive analysis by integrating results across multiple STAT targets. This enables a systems-level understanding of JAK/STAT interactions and how they influence the efficacy and safety of your therapeutic candidates, supporting data-driven optimization decisions.

Why Choose Our JAK/STAT Selectivity Panels

Creative Biolabs' JAK/STAT selectivity panel screening service offers a comprehensive platform to assess the activation and inhibition of STAT pathways, which is vital for the development and optimization of therapeutic candidates. By evaluating how investigational antibodies or proteins influence STAT signaling, researchers can screen and select the most promising candidates for further development.

• Comprehensive Screening: Our panels are tailored to focus on specific STATs, including STAT1, STAT3, STAT4, STAT5, and STAT6. Depending on your research goals, you can choose from single or multiple STAT reporter assays. This allows for precise analysis of the impact of potential therapeutic candidates on different STAT pathways.
• High-Throughput Capability: The screening process is optimized for high-throughput settings, providing rapid and reliable results that accelerate the drug discovery timeline.
• High-Sensitivity Detection: Our assays use high-sensitivity reporter systems, providing precise quantification of STAT pathway activation or inhibition. This allows for accurate assessment of dose-response relationships and early detection of pathway modulation.
• Data Integration: Our service includes the ability to integrate data from multiple panels, providing a holistic view of how different STAT proteins interact and influence therapeutic efficacy.

Partner with Creative Biolabs

The JAK/STAT selectivity panel screening service at Creative Biolabs is an invaluable tool for researchers engaged in therapeutic antibody and protein development. By providing tailored, cell-based assays that focus on JAK/STAT pathways, we empower scientists to deepen their understanding of JAK/STAT signaling pathways and their implications in health and disease. Whether you are investigating new therapeutic candidates or exploring the intricacies of immune responses, our service is designed to support your research goals effectively. For more information about our JAK/STAT selectivity panel screening service or to discuss your specific research needs, please contact us today.

Reference

1. Zhou, Qingluo, et al. "The potential roles of JAK/STAT signaling in the progression of osteoarthritis." Frontiers in Endocrinology 13 (2022): 1069057. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use